RUS
BIOPHARM
BioPharmaceutical Company
Our mission
Our Mission is to improve the quality of life and longevity of Patients.

We are developing and implementing Innovative approaches in BioPharmaceuticals to better serve Patients with life-impacting diseases.

Every Patient in the world has the right to Quality Medical treatment. Our goal is to make it affordable.

Who We Are
Rus BioPharm was founded in 2012, as an Integrated full-cycle BioPharmaceutical Company with a focus on:

  • Biological Products and Biosimilars
  • Innovative Drugs
  • Targeted Therapy Drugs
Rus BioPharm is focused on manufacturing of complex generics and biosimilars for severe diseases, including orphan indications.

Rus BioPharm's R&D efforts are directed towards development of well know molecules as well as combination of drugs previously not available in Russia. These combination drugs would vastly enhance the quality of life of the patients and make the drugs more affordable.

Rus BioPharm is also working on development of innovative drugs and biological drugs, with a focus on auto-immune diseases.
Whom We Serve
  • Patients in need of high quality and affordable drugs
  • We develop innovations and localize the production of medicines to increase the availability of medicines for patients
60
60 Drug Products in development
8
8 of which are Biosimilars
9
Facility fully equipped to manufacture 9 Drug Forms
Our Team
Rus BioPharm is a team of highly trained professionals with vast experience and key knowledge of the Pharmaceutical Industry
Satya Karm Punia
President and Founder of Rus BioPharm Group
Olga Turchaninova
Director General
Sumit Seth
Head of International Business Development
Denis Novakovsky
Head of Marketing and Sales

30+

More than 30 experienced professionals in R&D
150+

More than 150 employees at the manufacturing facility in Special Economic Zone, Dubna City, Moscow Region.
Lead Therapeutic Areas
Rus BioPharm is actively substituting imported Drug Products through development and local manufacturing of highly effective and expensive Drug Products, especially the ones listed in the Essential Drugs List.


Along with the Generic Drugs and Biosimilars, Rus BioPharm is also developing and launching novel Drug Products in the Russian market.
The lead therapeutic areas are as follows:
Pulmonology
Rheumatology
Oncology
Anti-Retrovials
Neurology
Gastroenterology
Assisted Reproductive Technologies
Anesthesiology and Intensive Care Therapies
Orphan Diseases

Our Products
Biological Products and Biosimilars
One of the key focus area of Rus BioPharm is development of Biological and Biosimilar Drug Products for severe Rheumatology, Onco-Hematology, Gastroenterology and Reproductive disorders.
6 additional Biosimilars in different stages of development

Inhalation Drugs
Pulmonology is one of the key focus areas for Rus BioPharm and Rus BioPharm is developing a wide range of Inhalation Drugs Products for Asthma and Chronic Obstructive Pulmonary Disease, in all possible Drug Forms: Aerosols, Powders, Solutions and Suspensions for inhalation
Metered Dose Inhalers
And more than 4 innovative products at the development stage
Dry Powder Inhalers
And more than 5 innovative products at the development stage (R&D)
Solutions and Suspensions for Inhalation
More than 7 products are under development

Sterile Injectables
Rus BioPharm is developing a wide range of Drugs Products for Hospital segment, such as new generation Antibiotics, Antimycotics, Proton pump inhibitors and a number of other Drugs from the Essential Drugs List, in 3 Drug forms: lyophilizates, Solutions and Concentrates.
More than 13 products are under development

Solid Dosage Forms
Rus BioPharm's OSD Drug Product range covers diseases such as HIV, Rheumatoid Arthritis, Multiple Sclerosis, Psoriasis, etc.
More than 4 products are under development

Manufacturing
Rus BioPharm's manufacturing facility is equipped with the latest and best available technology to effectively manufacture finished Drug Products with high added-value.
Rus BioPharm's manufacturing facility is equipped with the latest and best available technology to effectively manufacture finished Drug Products with high added-value.
1
Robust Fill & Finish lines to cover all Drug Forms
2
Implementation of the latest GxP Practices
3
Highly productive manufacturing process with no compromise on Quality
4
Continuous professional development of highly skilled employees

Pharmaceutical Capabilities
Metered Dose Inhalers
Dry Powder Inhalers
Metered Dose Solutions for Inhalation
Lyophilizates
Solutions and Concentrates for Injections
Solid Dosage Forms
Biological Drugs and Biosimilars – Injectable Solutions
Kilo Lab for API synthesis
Bioprocessing unit with USP and DSP

Quality control
All Products are manufactured at a modern facility that was completed in 2019.
The plant is equipped with all the necessary manufacturing and analytical equipment, to carry out most vigorous Quality Control assays.
Rus BioPharm uses New Generation Impactors to analyze Inhalation Drug forms, to determine the exact amount of API that penetrates the lungs during inhalation. This is a key characteristic of these Drug forms. Rus BioPharm also uses Sympatec to analyze the distribution of particle sizes, to efficiently analyze the quality of the API used.
Microbiological and Analytical laboratories have the necessary equipment for the analysis of Biological Products with latest technology and methods.

Vacancy
Our multinational team brings together professionals in various areas of the pharmaceutical industry. We are constantly developing and striving to implement advanced innovative solutions for the benefit of patients.
If you want to be a part of Rus BioPharm team, we are waiting for your resumes at hr@rusbiopharm.ru
    Contacts
    Headquarters
    29th Floor, Office E1
    Federation Tower East
    12, Presnenskaya Embankment
    Moscow, Russian Federation, 123100
    Phone: +7 499 400 16 99
    E-mail: office@rusbiopharm.ru

    Manufacturing Facility
    5/1-6, Programmistov Street
    Special Economic Zone "Dubna"
    Dubna, Moscow Region
    Russian Federation, 141983